Bromocriptine: old drug, new formulation and new indication (Q34145883)

31 July 2017

title

Bromocriptine: old drug, new formulation and new indication (English)

1 reference

31 July 2017

R. I G. Holt

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20977575

10 August 2024

C. J. Bailey

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20977575

10 August 2024

A. H. Barnett

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20977575

10 August 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20977575

10 August 2024

publication date

1 December 2010

1 reference

full work available at URL

31 July 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1463-1326.2010.01304.x

1 reference

DOI

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1463-1326.2010.01304.x/fullpdf

10 August 2024

1 reference

DOI

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Diabetes, Obesity and Metabolism

10 August 2024

published in

1 reference

31 July 2017

1 reference

31 July 2017

1 reference

31 July 2017

page(s)

1048-1057

1 reference

CNS regulation of glucose homeostasis

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01304.X

Diurnal variation in glucose tolerance. Cyclic suppression of insulin action and insulin secretion in normal-weight, but not obese, subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2010.01304.X

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Effect of bromocriptine on maturity onset diabetes

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Bromocriptine--unique formulation of a dopamine agonist for the treatment of type 2 diabetes

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Fate and disposition of bromocriptine in animals and man. II: Absorption, elimination and metabolism

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Pharmacokinetic evaluation of erythromycin and caffeine administered with bromocriptine

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Disruption of circadian insulin secretion is associated with reduced glucose uptake in first-degree relatives of patients with type 2 diabetes

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Evidence for a circadian rhythm of insulin sensitivity in patients with NIDDM caused by cyclic changes in hepatic glucose production

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Polymorphisms of serotonin receptor 2A and 2C genes and COMT in relation to obesity and type 2 diabetes

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Mutational analysis of the serotonin receptor 5HT2c in severe early-onset human obesity.

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Obesity, serious mental illness and antipsychotic drugs.

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Molecular clocks, type 2 diabetes and cardiovascular disease.

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Serotonin and energy balance: molecular mechanisms and implications for type 2 diabetes

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Dopamine is required for hyperphagia in Lep(ob/ob) mice

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Compensatory weight gain due to dopaminergic hypofunction: new evidence and own incidental observations

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

A randomized, double-blind, placebo-controlled trial to assess safety and tolerability during treatment of type 2 diabetes with usual diabetes therapy and either Cycloset or placebo

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricetus auratus)

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Simultaneous silencing of Npy and Dbh expression in hindbrain A1/C1 catecholamine cells suppresses glucoprivic feeding

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Hindbrain catecholamine neurons control multiple glucoregulatory responses

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Hypothalamic dopamine and serotonin in the regulation of food intake.

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Effect of Adrenocortical Hormones on Activity of the Serotoninergic System in Limbic Structures in Rats

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Changes in circadian rhythms and sleep quality with aging: mechanisms and interventions

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Impaired prolactin secretion and body fat distribution in obesity

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Simultaneous study of cortisol, growth hormone and prolactin nyctohemeral variations in normal and obese subjects. Influence of prolonged fasting in obesity

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Chronic infusion of norepinephrine into the ventromedial hypothalamus induces obesity in rats

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Relationships between brain noradrenergic activity and blood glucose

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Association of the antidiabetic effects of bromocriptine with a shift in the daily rhythm of monoamine metabolism within the suprachiasmatic nuclei of the Syrian hamster.

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Bromocriptine alters hormone rhythms and lipid metabolism in swine

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Effects of a Quick-Release Form of Bromocriptine (Ergoset) on Fasting and Postprandial Plasma Glucose, Insulin, Lipid, and Lipoprotein Concentrations in Obese Nondiabetic Hyperinsulinemic Women

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Lack of evidence for bromocriptine effect on glucose tolerance, insulin resistance, and body fat stores in obese type 2 diabetic patients.

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Bromocriptine: a novel approach to the treatment of type 2 diabetes.

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Does bromocriptine improve glycemic control of obese type-2 diabetics?

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

The effects of prolonged bromocriptine administration on PRL secretion GH and glycaemic control in stable insulin-dependent diabetes mellitus

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Interaction of bromocriptine and cyclosporine in insulin dependent diabetes mellitus: results from the Canadian open study.

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

Dopamine agonists and the risk of cardiac-valve regurgitation

10 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1463-1326.2010.01304.X

10 August 2024

Identifiers

DOI

1 reference

31 July 2017

1 reference